Login| Sign Up| Help| Contact|

Patent Searching and Data


Title:
IMMUNOMODULATORY COMPOUNDS, COMPOSITION AND APPLICATION THEREOF
Document Type and Number:
WIPO Patent Application WO/2021/093817
Kind Code:
A1
Abstract:
Disclosed are a class of amide compounds having novel structures or stereoisomers thereof or stereoisomer mixtures thereof and pharmaceutically acceptable salts thereof, and application thereof in the preparation of drugs for the treatment of diseases, disorders, or conditions that benefit from the inhibition of PD1 or PD-L1 activity. The compounds of the present invention exhibit strong PD-1/PD-L1 blocking activity, and can reverse the T cell function inhibited by PD-L1. In addition, the compounds of the present invention can activate the NFAT signal pathway caused by the binding of PD-1/PD-L1, and can be absorbed orally, and have good pharmacokinetic properties. Therefore, the compounds of the present invention can be applied, alone or in combination with other drugs, in the treatment of diseases, disorders, or conditions that benefit from the inhibition of PD1 or PD-L1 activity, comprising infectious diseases, immune diseases, inflammatory diseases, and cancer.

Inventors:
ZHOU XINGLU (CN)
LIU XINGGUO (CN)
HU MIAO (CN)
Application Number:
PCT/CN2020/128435
Publication Date:
May 20, 2021
Filing Date:
November 12, 2020
Export Citation:
Click for automatic bibliography generation   Help
Assignee:
HANGZHOU HERTZ PHARMACEUTICAL CO LTD (CN)
International Classes:
C07D487/04; A61K31/437; A61P35/00; A61P37/00; C07D471/04; C07D513/04
Domestic Patent References:
WO2018119224A12018-06-28
WO2020232256A12020-11-19
Foreign References:
CN109890819A2019-06-14
CN101861307A2010-10-13
Other References:
YOUNG, W.B. ET AL.: "Potent and selective Bruton's tyrosine kinase inhibbitors: Discovery of GDC-0834", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 25, no. 6, 15 March 2015 (2015-03-15), pages 1333 - 1337, XP002772334, ISSN: 0960-894X, DOI: 10.1016/j.bmcl.2015.01.032
Attorney, Agent or Firm:
HANGZHOU ZHIXIAN PATENT AGENCY (CN)
Download PDF: